? PLANNING AND EVALUATION The mission of Fox Chase Cancer Center (FCCC) is to prevail over cancer, marshaling heart and mind in bold scientific discovery, pioneering prevention, and compassionate care. In order to execute this mission, FCCC relies on a comprehensive Planning and Evaluation system that encompasses all Research Programs, Shared Resources, clinical departments, and administration. This structure monitors the Center?s progress relative to the Strategic Plan, the needs of the FCCC?TU catchment area, and the national cancer program.
The Specific Aims of FCCC?s Planning and Evaluation activity are to ensure effective and well-coordinated use of all Cancer Center Support Grant resources, institutional investment, and philanthropic funds in service of the Center?s mission; and to establish a direction for the Center?s Research Program development. Planning and Evaluation incorporates advice from the FCCC External Advisory Committee (EAC) and its Internal Advisory Committee (IAC), as well as from a multi-tiered leadership and governance structure. Fisher, as Cancer Center Director, has the authority and ultimate responsibility for execution of the strategic plan, organizing the Center, setting priorities for the development of new Research Programs and Shared Resources, recruiting and retaining junior scientists and academic leaders, dispensing developmental funds to junior faculty support and pilot grants, and optimizing space and resource utilization. He relies on Deputy Director and Chief Scientific Officer Chernoff and the other Deputy Directors (El-Deiry and Beck) to manage the various components of the Center and chair internal planning efforts. Fisher chairs the weekly Cancer Center Leadership Committee (CCLC), comprising the Deputy and Associate Directors, Vice President for Research Administration (VPRA) Gricoski, Research Program leaders and clinical department chairs. Ideas for recruitment, scientific initiatives and Shared Resources arise at the Program level, are brought to the CCLC for discussion and prioritization, then to biweekly meetings of the Deputy Directors, VPRA and Fisher. CCLC also reviews evaluative reports arising from Research Program retreats, EAC and IAC meetings, and the Facilities Parent Oversight Committee (Shared Resources). Reports from internal and external consulting groups are incorporated into strategic planning, generating a living and forward looking statement of Fox Chase?s direction and activities for the ensuing five years.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006927-52
Application #
9331451
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2017-08-01
Budget End
2018-07-31
Support Year
52
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Research Institute of Fox Chase Cancer Center
Department
Type
DUNS #
064367329
City
Philadelphia
State
PA
Country
United States
Zip Code
19111
Reese, Jennifer Barsky; Smith, Katherine Clegg; Handorf, Elizabeth et al. (2018) A randomized pilot trial of a couple-based intervention addressing sexual concerns for breast cancer survivors. J Psychosoc Oncol :1-22
Shaikh, Talha; Handorf, Elizabeth A; Meyer, Joshua E et al. (2018) Mismatch Repair Deficiency Testing in Patients With Colorectal Cancer and Nonadherence to Testing Guidelines in Young Adults. JAMA Oncol 4:e173580
Roy, Anuradha (2018) Early Probe and Drug Discovery in Academia: A Minireview. High Throughput 7:
Auerbach, M V; Heckman, C J; Darlow, S (2018) To protect or not to protect: examining reasons for sun protection among young women at risk for skin cancer. J Behav Med 41:528-536
Diefenbach, Michael A; Benedict, Catherine; Miller, Suzanne M et al. (2018) Examining the impact of a multimedia intervention on treatment decision-making among newly diagnosed prostate cancer patients: results from a nationwide RCT. Transl Behav Med 8:876-886
Ross, Kayleigh C; Chin, Kevin F; Kim, Daehwan et al. (2018) Methotrexate sensitizes drug-resistant metastatic melanoma cells to BRAF V600E inhibitors dabrafenib and encorafenib. Oncotarget 9:13324-13336
Shafi, Ayesha A; Schiewer, Matthew J; de Leeuw, Renée et al. (2018) Patient-derived Models Reveal Impact of the Tumor Microenvironment on Therapeutic Response. Eur Urol Oncol 1:325-337
Mazor, Anna M; Mateo, Alina M; Demora, Lyudmila et al. (2018) Breast conservation versus mastectomy in patients with T3 breast cancers (>?5 cm): an analysis of 37,268 patients from the National Cancer Database. Breast Cancer Res Treat :
Ingram, Justin P; Tursi, Sarah; Zhang, Ting et al. (2018) A Nonpyroptotic IFN-?-Triggered Cell Death Mechanism in Nonphagocytic Cells Promotes Salmonella Clearance In Vivo. J Immunol 200:3626-3634
Chang, Wen-Chi L; Jackson, Christina; Riel, Stacy et al. (2018) Differential preventive activity of sulindac and atorvastatin in Apc+/Min-FCCCmice with or without colorectal adenomas. Gut 67:1290-1298

Showing the most recent 10 out of 1280 publications